ClinicalTrials.gg
RecruitingNCT07017270GUARD-1Updated Jun 26, 2026

Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis

A Phase 4 interventional study of Semaglutide Pen in Kidney Disease, Chronic, Diabetes and Dialysis, sponsored by Unity Health Toronto. Recruiting at 2 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-26.

Primary conditionKidney Failure, ChronicRegistry: Renal Insufficiency, ChronicReclassifiedWhy we changed it
Registry
Renal Insufficiency, Chronic — the first condition term the registry derived for this study.
ClinicalTrials.gg
Kidney Failure, Chronic
Why
  1. The study's listed conditions name Kidney Failure, Chronic, a narrower term within Renal Insufficiency, Chronic.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Unity Health Toronto · Phase 4, Interventional, and Treatment

How we know · 2 judgments

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 134 studies in Kidney Failure, Chronic with a site in Canada — 20 open to participants now, 28 under way, 4 of them phase 3. Kidney Failure, Chronic · Canada.

Planned enrollment
48th of 110
100 · median 79
Started
2025
with 3 others
Phase 4
11 of 134
2 open now
Primary completion
2027-07
later than 15 of 27 live
Registered
131st of 134
by date
Lead sponsor
5 of 134
Unity Health Toronto

Among the 134 studies in Kidney Failure, Chronic with a site in Canada, this one is the 48th largest by planned enrollment of the 110 interventional ones that give a count, is one of 4 that started in 2025, is one of 11 in phase 4, reaches primary completion later than 15 of the 27 other live ones, and was the 131st registered.

Kidney Failure, Chronic

2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

20 of the 134 studies in Kidney Failure, Chronic with a site in Canada are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 134 studies in Kidney Failure, Chronic with a site in Canada, or all of them as a file.
02

Study summary

This study aims to determine if GLP1RA is safe and tolerable in maintenance dialysis population, adherence, and feasibility of a larger definitive cardiovascular outcome trial in this population. Participants will be randomized 1:1 to either weekly subcutaneous semaglutide versus usual care and followed for 26 weeks.

Read the detailed description

The proposed study is a parallel group, pilot randomized controlled trial. The trial will recruit 100 participants across Canadian hospitals and potentially others worldwide. We will recruit patients receiving maintenance dialysis for ≥ 90 days who have a background of type 2 diabetes mellitus. We will exclude patients with type 1 diabetes mellitus and recent recipients of a GLP-1-RA. Participants will be randomized 1:1 to either weekly subcutaneous semaglutide versus usual care and followed for 26 weeks. The key feasibility outcomes are: (1) successful recruitment of fully eligible patients (≥40%); (2) adherence to the study intervention (≥70% participants take at least 70% of prescribed study drug doses); and (3) completeness of follow-up (≥90% participants are successfully followed to 26 weeks). Secondary outcomes will include adverse events, major adverse cardiovascular events, changes in body weight, glycemic control, insulin dosage, blood pressure, lipid parameters, markers of CKD-related bone mineral disease, and quality of life.

As a pilot RCT, GUARD-1 will focus on the safety and tolerability of the GLP-1-RA semaglutide in the maintenance dialysis population. The key question of this trial is whether an RCT to evaluate the cardiovascular effects of GLP-1-RA in the maintenance dialysis population is feasible based on study recruitment, adherence, follow-up and safety.

03

Conditions studied

  • Kidney Disease, Chronic
  • Diabetes
  • Dialysis
  • End Stage Kidney Disease (ESRD)

Keywords

  • Dialysis
  • Type 2 diabetes
  • semaglutide
  • end stage kidney disease
  • GLP1
  • GLP1RA
04

In context

Kidney Failure, Chronic Reclassified

2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.

This study's planned enrollment of 100 is above the median of 57 across 1,573 interventional studies indexed under Kidney Failure, Chronic.

Browse Kidney Failure, Chronic studies →

Lead sponsor

Unity Health Toronto is the lead sponsor of 447 studies on the registry; 81 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Compared within Kidney Failure, Chronic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Renal Insufficiency, Chronic. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18
  2. Receiving chronic maintenance hemodialysis or peritoneal dialysis for ≥ 90 days
  3. confirmed DM2 based on medical history and current or prior receipt of an oral hypoglycemic agent and/or insulin.
  4. Ability to provided or through their substitute decision maker

Exclusion criteria

Exclusion Criteria:

  1. Type 1 DM
  2. Use of a GLP-1-RA within 30 days prior to screening
  3. Personal or first-degree relative(s) with a history of type 2 multiple endocrine neoplasia syndrome or medullary thyroid cancer, or acute pancreatitis (within 180 days of study screening)
  4. Confirmed pregnancy, women of
  5. Known to GLP-1-RA
  6. Expected to recover kidney function, stop hemodialysis, pursue palliative care, or transplantation within 6 months
  7. Enrolment in another clinical trial judged by the investigator to interact with the effect of GLP1-RA
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • No intervention
    Usual Care Group

    This treatment arm comprises a strategy of usual care for type 2 diabetes mellitus

  • Experimental
    Semaglutide

    Individuals randomized to this arm will take semaglutide once weekly.

    Drug: Semaglutide Pen

Interventions

  • DrugSemaglutide Pen

    Individuals randomized to this arm will take semaglutide once weekly. For participants receiving in-centre hemodialysis, the intervention may be administered during the dialysis session by nursing personnel based on the patient's preference.

This study also gives SemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

07

What researchers measure

Primary outcomes

  1. Adherence of Study Intervention

    This will be determined if ≥ 70% of enrolled number of eligible participants (who are randomized) are adherent to the study intervention over the 26-week follow-up period.

    Time frame: 26 weeks

Secondary outcomes

  1. Study Medication Discontinuation

    The number of enrolled participants who permanently discontinue the study medication in the semaglutide arm from baseline to 6 months.

    Time frame: 26 weeks

  2. Feasibility of Study Recruitment

    This will be determined if ≥ 40% of the number of fully eligible participants (potential participants who were screened and identified to meet inclusion/exclusion criteria) consent to participate in the trial.

    Time frame: 26 weeks

  3. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    We will measure the incidence of Treatment-Emergent Adverse Events \[Safety and Tolerability\] and identify safety events of special interest such as gastrointestinal symptoms, acute biliary disease, acute pancreatitis, interventions for diabetic retinopathy, heart failure exacerbations, malignant neoplasms, and the number of hypoglycemic events.

    Time frame: 26 weeks

  4. Major Adverse Cardiovascular Events

    This is a composite of CV death, non-fatal myocardial infarction, non-fatal stroke, or a peripheral arterial event.

    Time frame: 26 weeks

  5. Follow Up Percentage at 26 weeks

    To determine if ≥ 90% of participants (who are enrolled) will be successfully followed to week 26 (end of study participation).

    Time frame: 26 weeks

  6. Patient Reported Measures

    The validated EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) score will be used to evaluate baseline-adjusted changes in quality of life and symptom burden. The EQ-5D-5L asks individuals to rate their overall health on a visual scale from 0 to 100, where 0 represents the worst imaginable health and 100 represents the best imaginable health.

    Time frame: 26 weeks

08

Study locations

2 of 2 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Jul 2027, 20 months after the start.

Of 52 non-industry phase 4 interventional studies under Kidney Failure, Chronic, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 80. This study's planned 20 months is below that.

Counting every sponsor, half of 63 studies reached it within 31 months; a quarter within 16 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2025
First posted
Jun 12, 2025
StartActual
Nov 27, 2025
Primary completionEst.
Jul 2027
CompletionEst.
Sep 2027
Last update
Jun 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07017270
Responsible party
Sponsor
First posted
Jun 12, 2025
Start date
Nov 27, 2025
Primary completion
Jul 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Jun 26, 2026

Study contacts

Ron Wald, MD
Contact
ron.wald@unityhealth.to
(416) 867-3703
Kevin Yau, MD
Contact
Kevin.Yau@uhn.ca
Dr. Ron Wald, MD
principal investigator · Unity Health Toronto

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion